AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: High ALP level
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: Low LDH level
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: High LDH level
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: High SUV1 in EWS patients
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SUV1 in EWS patients
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: High SUV1 in OS patients
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SUV1 in OS patients
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: High SUV2 in EWS patients
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SUV2 in EWS patients
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: Good metabolic response (SUV reduction of ≥55%)
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor metabolic response
Number of subjects: 77
Study 25435403 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal Shock Wave Lithotripsy (ESWL)
Number of subjects: 55
Study 25435403 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde Intrarenal Surgery (RIRS)
Number of subjects: 55
Study 23294997 — intervention group
Group type: EXPERIMENTAL
Intervention: Known diabetes mellitus (DM)
Number of subjects: 320
Study 23294997 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HbA1c ≥6.5%
Number of subjects: 320
Study 23294997 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HbA1c ≥5.7%
Number of subjects: 320
Study 23294997 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cardiac events
Number of subjects: 320
Study 21982313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy-defibrillator (CRT-D)
Number of subjects: 0
Study 18507661 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin plus 1 mg glucagon
Number of subjects: 6
Study 18507661 — intervention group
Group type: COMPARATOR
Intervention: 100 mg indomethacin alone (placebo)
Number of subjects: 6
Study 16412642 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated slips using a custom slipping platform
Number of subjects: 22
Study 16412642 — intervention group
Group type: COMPARATOR
Intervention: Actual slips induced with artificial ice
Number of subjects: 22
Study 14642039 — intervention group
Group type: EXPERIMENTAL
Intervention: End-hole + sidehole catheters
Number of subjects: 22
Study 10348155 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with epilepsy
Number of subjects: 345
Study 10348155 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with epilepsy using phenytoin
Number of subjects: 345
Study 10348155 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with epilepsy with family fracture history
Number of subjects: 345
Study 10348155 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 345
Study 7561530 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TB chemotherapy with rifampicin (isoniazid, pyrazinamide, ethambutol, and rifampicin)
Number of subjects: 80
Study 7561530 — intervention group
Group type: COMPARATOR
Intervention: Anti-TB chemotherapy without rifampicin (isoniazid, pyrazinamide, and ethambutol)
Number of subjects: 80
Study 7561530 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TB chemotherapy with rifampicin
Number of subjects: 80
Study 7561530 — intervention group
Group type: COMPARATOR
Intervention: Anti-TB chemotherapy without rifampicin
Number of subjects: 80
Study 1766577 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of reduced GSH for 30 days
Number of subjects: 80
Study 1766577 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of vitamin K for 30 days
Number of subjects: 80
Study 7184670 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide tablet (250 mg)
Number of subjects: 18
Study 7184670 — intervention group
Group type: COMPARATOR
Intervention: Chlorpropamide suspension
Number of subjects: 18
Study 29397638 — intervention group
Group type: EXPERIMENTAL
Intervention: OTSC® Proctology
Number of subjects: 30
Study 29397638 — intervention group
Group type: COMPARATOR
Intervention: Fistulectomy with primary sphincter reconstruction
Number of subjects: 30
Study 28609641 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility training (3×/week; 30 min/day)
Number of subjects: 25
Study 28609641 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of intense eccentric exercise
Number of subjects: 25
Study 28609641 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 25
Study 25197738 — intervention group
Group type: EXPERIMENTAL
Intervention: Flossing followed by brushing (FB)
Number of subjects: 35
Study 25197738 — intervention group
Group type: COMPARATOR
Intervention: Brushing followed by flossing (BF)
Number of subjects: 35
Study 24704427 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-directed prenatal education teaching module about vaccination pain management (20-30 minute interactive presentation)
Number of subjects: 197
Study 24704427 — intervention group
Group type: COMPARATOR
Intervention: General vaccination information (control group)
Number of subjects: 197
Study 22409394 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐ligating brackets
Number of subjects: 19
Study 22409394 — intervention group
Group type: COMPARATOR
Intervention: conventional preadjusted brackets
Number of subjects: 19
Study 19678780 — intervention group
Group type: EXPERIMENTAL
Intervention: C. domestica extracts 2 g per day for 6 weeks
Number of subjects: 107
Study 19678780 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 800 mg per day for 6 weeks
Number of subjects: 107
Study 19678780 — intervention group
Group type: EXPERIMENTAL
Intervention: C. domestica extracts
Number of subjects: 107
Study 19678780 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 107
Study 17181395 — intervention group
Group type: COMPARATOR
Intervention: Low volumetric total (D tot) and trabecular (D trab) BMDs, BV/TV, cortical thickness (Cort Th), trabecular number (TbN), trabecular thickness (TbTh), trabecular separation (TbSp), and distribution of trabecular separation (TbSpSd) at the distal radius
Number of subjects: 101
Study 17181395 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric total and trabecular densities
Number of subjects: 101
Study 17181395 — intervention group
Group type: COMPARATOR
Intervention: D trab, TbN, TbSp, and TbSpSd at the distal radius
Number of subjects: 101
Study 17181395 — intervention group
Group type: COMPARATOR
Intervention: D tot, D trab, Cort Th, and TbTh at the distal tibia
Number of subjects: 101
Study 15895286 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 1 mg/day p.o. for 3 months
Number of subjects: 203
Study 15895286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 12572869 — intervention group
Group type: EXPERIMENTAL
Intervention: Germinated barley foodstuff (GBF) 20-30 g daily for 4 weeks
Number of subjects: 18
Study 12572869 — intervention group
Group type: COMPARATOR
Intervention: Baseline anti-inflammatory therapy for 4 weeks
Number of subjects: 18
Study 9419167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free HIV‐1 in breast milk
Number of subjects: 75
Study 9734472 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA) at doses of 10(-10) to 10(-5) mol/L
Number of subjects: 70
Study 9734472 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-octadecynoic acid (17-ODYA) at 10(-5) mol/L (P450 inhibitor)
Number of subjects: 70
Study 9734472 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO) at 10(-5) mol/L (cyclooxygenase inhibitor)
Number of subjects: 70
Study 9734472 — intervention group
Group type: EXPERIMENTAL
Intervention: N omega-nitro-L-arginine methyl ester (L-NAME) at 10(-4) mol/L (NO synthase inhibitor)
Number of subjects: 70
Study 9734472 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole at 10(-5) mol/L (P450 inhibitor)
Number of subjects: 70
Study 9734472 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mmol/L KCl
Number of subjects: 70
Study 9734472 — intervention group
Group type: EXPERIMENTAL
Intervention: Charybdotoxin at 10(-8) mol/L (large-conductance Ca2+-activated K+ channel blocker)
Number of subjects: 70
Study 1894852 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg bite-and-swallow) after calcium infusion (10 ml of 10% calcium chloride in 50 ml of 5% dextrose in water)
Number of subjects: 17
Study 1894852 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg bite-and-swallow) after placebo infusion (5% dextrose in water)
Number of subjects: 17
Study 1894852 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium infusion (10 ml of 10% calcium chloride in 50 ml of 5% dextrose in water)
Number of subjects: 17
Study 1894852 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (5% dextrose in water)
Number of subjects: 17
Study 1894852 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg bite-and-swallow) after calcium infusion
Number of subjects: 17
Study 7051825 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 20
Study 7051825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31996108 — intervention group
Group type: EXPERIMENTAL
Intervention: New model of diabetes care introduced in 2008, which included continual monitoring, analysis, and adjustment of initiatives taken.
Number of subjects: 0
Study 31996108 — intervention group
Group type: EXPERIMENTAL
Intervention: New model of diabetes care
Number of subjects: 0
Study 30714984 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (n = 20)
Number of subjects: 60
Study 30714984 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation therapy (VRT) (n = 20)
Number of subjects: 60
Study 30714984 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of corticosteroids and vestibular rehabilitation (n = 20)
Number of subjects: 60
Study 26449210 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Australia Survey screening
Number of subjects: 0
Study 26449210 — intervention group
Group type: COMPARATOR
Intervention: Single-item screening tool
Number of subjects: 0
Study 24427649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg IV at induction of anesthesia)
Number of subjects: 90
Study 24427649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 21635675 — intervention group
Group type: COMPARATOR
Intervention: 25 mg prednisone
Number of subjects: 0
Study 21635675 — intervention group
Group type: COMPARATOR
Intervention: 10 mg prednisone
Number of subjects: 0
Study 17429559 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal purse-string suture (group 1)
Number of subjects: 40
Study 17429559 — intervention group
Group type: COMPARATOR
Intervention: No anal purse-string suture (group 2)
Number of subjects: 40
Study 16421063 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi group (n = 9)
Number of subjects: 18
Study 16421063 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list, n = 9)
Number of subjects: 18
Study 14605050 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid, 600 mg, q12h for 7 to 21 days
Number of subjects: 1019
Study 14605050 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin, 1 g, q12h for 7 to 21 days
Number of subjects: 1019
Study 11482708 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting tricuspid regurgitation velocity (TRV) and right ventricular outflow tract velocity curve (RVOTvc) indices
Number of subjects: 52
Study 11482708 — intervention group
Group type: COMPARATOR
Intervention: Healthy asymptomatic volunteers
Number of subjects: 52
Study 8632551 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum therapy
Number of subjects: 33
Study 8632551 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-injection
Number of subjects: 33
Study 1843544 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional toothbrushing with dentifrice
Number of subjects: 53
Study 1843544 — intervention group
Group type: COMPARATOR
Intervention: Professional toothbrushing with water
Number of subjects: 53
Study 6084461 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron prophylaxis
Number of subjects: 0
Study 6084461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31286387 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised 18-week high-intensity exercise program
Number of subjects: 109
Study 30312159 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualized Swedish massage therapy (SMT)
Number of subjects: 0
Study 30312159 — intervention group
Group type: EXPERIMENTAL
Intervention: Light touch (LT)
Number of subjects: 0
Study 26874330 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg orally)
Number of subjects: 24
Study 26874330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40mg orally)
Number of subjects: 24
Study 26874330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26874330 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvinorin-A (1mg vaporized)
Number of subjects: 24
Study 23884048 — intervention group
Group type: EXPERIMENTAL
Intervention: GMS1 (autocorrecting device)
Number of subjects: 12
Study 23884048 — intervention group
Group type: COMPARATOR
Intervention: GMS2 (noncorrecting device)
Number of subjects: 12
Study 22196125 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aquatic therapy (after 6 days)
Number of subjects: 465
Study 22196125 — intervention group
Group type: COMPARATOR
Intervention: Late aquatic therapy (after 14 days)
Number of subjects: 465
Study 21048810 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin and selenium (SM-Se) combination (570 mg of silymarin and 240 µg of selenium as selenomethionine)
Number of subjects: 37
Study 21048810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 16955461 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV antibody detection immunoassay
Number of subjects: 100
Study 16955461 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative polymerase chain reaction assay
Number of subjects: 100
Study 15908660 — intervention group
Group type: EXPERIMENTAL
Intervention: FU/LV/BV
Number of subjects: 923
Study 15908660 — intervention group
Group type: COMPARATOR
Intervention: IFL/placebo
Number of subjects: 923
Study 11914444 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (assessment, personalized self-study feedback, six face-to-face sessions)
Number of subjects: 501
Study 11914444 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial intervention (self-help group with assessment and personalized feedback by mail)
Number of subjects: 501
Study 11914444 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 501
Study 11914444 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (HMO subsample)
Number of subjects: 501
Study 9821996 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide administered to patients receiving norepinephrine
Number of subjects: 27
Study 9821996 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nitric oxide administered to patients not receiving norepinephrine
Number of subjects: 27
Study 9051541 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg (Group MH)
Number of subjects: 11
Study 9051541 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.035 mg/kg (Group ML)
Number of subjects: 11
Study 9051541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group PL)
Number of subjects: 11
Study 2527316 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic closed suction drainage on one side of the groin
Number of subjects: 50
Study 2527316 — intervention group
Group type: COMPARATOR
Intervention: Closure without drainage on the contralateral side of the groin
Number of subjects: 50
Study 1276560 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine group (antidepressive drug treatment)
Number of subjects: 0
Study 1276560 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (placebo treatment)
Number of subjects: 0
Study 1276560 — intervention group
Group type: COMPARATOR
Intervention: Natural Process group (no treatment)
Number of subjects: 0
Study 30738059 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery device (group B)
Number of subjects: 20
Study 30738059 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (group A)
Number of subjects: 20
Study 28409744 — intervention group
Group type: EXPERIMENTAL
Intervention: multiple‐modality exercise (M2)
Number of subjects: 58
Study 28409744 — intervention group
Group type: EXPERIMENTAL
Intervention: multiple‐modality plus mind‐motor exercise (M4)
Number of subjects: 58
Study 26152412 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidacloprid/Flumethrin Collar (Seresto)
Number of subjects: 24
Study 26152412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fipronil/(S)-Methoprene/Eprinomectin/Praziquantel Spot-on (Broadline)
Number of subjects: 24
Study 23209098 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 109
Study 23209098 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) for SSTI
Number of subjects: 109
Study 21421014 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐2, 1600 μg subcutaneously (SC)
Number of subjects: 8
Study 21421014 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 8
Study 19333166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg, 3 times daily)
Number of subjects: 36
Study 19333166 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet, 3 times daily)
Number of subjects: 36
Study 19333166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 36
Study 19333166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16943675 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with standardized latex extract
Number of subjects: 23
Study 16943675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 15157351 — intervention group
Group type: EXPERIMENTAL
Intervention: UPBEAT Program (interdisciplinary mental health care management program)
Number of subjects: 2637
Study 15157351 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2637
Study 15157351 — intervention group
Group type: EXPERIMENTAL
Intervention: UPBEAT Program
Number of subjects: 2637
Study 11380295 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA (manual vacuum aspiration)
Number of subjects: 200
Study 11380295 — intervention group
Group type: COMPARATOR
Intervention: VA (conventional vacuum aspiration)
Number of subjects: 200
Study 9230243 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice daily for 6 months
Number of subjects: 262
Study 9230243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 9230243 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 262
Study 8106830 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 15
Study 8106830 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic group (control)
Number of subjects: 15
Study 3318371 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI 201-106 (80 mg and 100 mg)
Number of subjects: 15
Study 29705466 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga Group (YG)
Number of subjects: 30
Study 29705466 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet Group (PG)
Number of subjects: 30
Study 27737685 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based multidisciplinary rehabilitation intervention
Number of subjects: 620
Study 27737685 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 620
Study 24229842 — intervention group
Group type: EXPERIMENTAL
Intervention: Manner of drinking (MOD)
Number of subjects: 338
Study 24229842 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious harm reduction (SHR)
Number of subjects: 338
Study 24229842 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping/limiting drinking (SLD)
Number of subjects: 338
Study 22866998 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based PAC intervention
Number of subjects: 0
Study 22866998 — intervention group
Group type: COMPARATOR
Intervention: PEP-based PAC intervention
Number of subjects: 0
Study 20386077 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 900/100 mg once daily
Number of subjects: 30
Study 20386077 — intervention group
Group type: COMPARATOR
Intervention: darunavir/ritonavir 600/100 mg twice daily
Number of subjects: 30
Study 18561543 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel words with English plural inflection
Number of subjects: 24
Study 18561543 — intervention group
Group type: COMPARATOR
Intervention: Novel words without English plural inflection
Number of subjects: 24
Study 16032944 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (Eludril) irrigation associated with scaling
Number of subjects: 0
Study 16032944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (Dakin Cooper) irrigation associated with scaling
Number of subjects: 0
Study 16032944 — intervention group
Group type: COMPARATOR
Intervention: Scaling alone
Number of subjects: 0
Study 12492907 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan solubilized in alcohol
Number of subjects: 19
Study 12492907 — intervention group
Group type: COMPARATOR
Intervention: Triclosan solubilized in oil
Number of subjects: 19
Study 12492907 — intervention group
Group type: COMPARATOR
Intervention: Triclosan solubilized in uncharged detergent
Number of subjects: 19
Study 12492907 — intervention group
Group type: COMPARATOR
Intervention: Triclosan solubilized in chromophor
Number of subjects: 19
Study 12492907 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan solubilized in sodium lauryl sulphate, propylene glycol and water
Number of subjects: 19
Study 10063942 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg twice daily
Number of subjects: 62